FDA approves Novartis breakthrough therapy cancer drug


The FDA gives a thumbs up to Novartis' (NVS +1.2%) Zykadia (ceritinib) as a treatment for patients with a certain type of late-stage (metastatic) non-small cell lung cancer months ahead of schedule.

Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks cancer cell-promoter proteins.

The agency granted Zykadia breakthrough therapy designation, priority review and orphan drug designation. Its clearance comes four months ahead of the August 24 PDUFA date.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs